Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 7
1988 8
1989 14
1990 18
1991 16
1992 9
1993 13
1994 11
1995 14
1996 13
1997 12
1998 11
1999 12
2000 11
2001 18
2002 7
2003 11
2004 13
2005 15
2006 20
2007 15
2008 15
2009 16
2010 23
2011 22
2012 22
2013 29
2014 18
2015 33
2016 23
2017 16
2018 17
2019 25
2020 28
2021 34
2022 43
2023 29
2024 17

Search Results

599 results

Results by year

Filters applied: . Clear all
Page 1
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
Primary Hyperoxaluria.
Xie X, Zhang X. Xie X, et al. N Engl J Med. 2022 Mar 10;386(10):976. doi: 10.1056/NEJMicm2113369. Epub 2022 Mar 5. N Engl J Med. 2022. PMID: 35245013 No abstract available.
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Michael M, et al. Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. doi: 10.1053/j.ajkd.2022.05.012. Epub 2022 Jul 14. Am J Kidney Dis. 2023. PMID: 35843439 Free article. Clinical Trial.
Oxalate Maculopathy.
Kourti P, Gonzalez-Martin J, Yeo DCM. Kourti P, et al. Ophthalmol Retina. 2020 Sep;4(9):898. doi: 10.1016/j.oret.2020.04.008. Ophthalmol Retina. 2020. PMID: 32896362 No abstract available.
Primary Hyperoxaluria.
Jiang D, Geng H. Jiang D, et al. N Engl J Med. 2017 Apr 13;376(15):e33. doi: 10.1056/NEJMicm1609986. N Engl J Med. 2017. PMID: 28402768 Free article. No abstract available.
Pathophysiology and management of enteric hyperoxaluria.
Joly PF. Joly PF. Clin Res Hepatol Gastroenterol. 2024 Jun;48(6):102359. doi: 10.1016/j.clinre.2024.102359. Epub 2024 May 10. Clin Res Hepatol Gastroenterol. 2024. PMID: 38734370 No abstract available.
Pathophysiology and management of enteric hyperoxaluria.
Desenclos J, Forté V, Clément C, Daudon M, Letavernier E. Desenclos J, et al. Clin Res Hepatol Gastroenterol. 2024 May;48(5):102322. doi: 10.1016/j.clinre.2024.102322. Epub 2024 Mar 19. Clin Res Hepatol Gastroenterol. 2024. PMID: 38503362 Free article. Review.
Investigational Therapies for Primary Hyperoxaluria.
Kletzmayr A, Ivarsson ME, Leroux JC. Kletzmayr A, et al. Bioconjug Chem. 2020 Jul 15;31(7):1696-1707. doi: 10.1021/acs.bioconjchem.0c00268. Epub 2020 Jun 29. Bioconjug Chem. 2020. PMID: 32539351 Review.
599 results